EVER Pharma
EVER Pharma is a privately held, family-owned Austrian specialty pharmaceutical company developing, manufacturing, and selling differentiated injectable generics and CDMO services across neurology, oncology, anesthesia, and critical care in 70+ countries.
- Company typePrivate
- Founded1934
- HeadquartersUnterach, Austria
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What EVER Pharma does
EVER Pharma is a privately held, family-owned specialty pharmaceutical company founded in 1934 and headquartered in Unterach, Austria. The company develops, manufactures, and commercializes a portfolio of branded specialty generic injectable pharmaceuticals across neurology, oncology, anesthesia, and critical care therapeutic areas. Its product range includes differentiated formulations such as room-temperature-stable Fulvestrant (the first in Europe), ready-to-use liquid Bortezomib, single-vial Cabazitaxel, and a complete Parkinson's disease therapy package combining Apomorphine (Dacepton) with proprietary micro-infusion devices (D-mine Pump, D-mine Pen). Manufacturing is concentrated in two EU GMP-certified facilities: the Unterach headquarters and R&D center (140+ employees), and the Jena, Germany production campus (350 employees, opened 2023 following a €200M+ investment) producing over 400 pharmaceutical products across vials, ampoules, pre-filled syringes, cartridges, and implants.
EVER Pharma generates revenue through two streams: (1) direct product sales of specialty generic injectables to hospitals, clinics, and healthcare professionals via wholly-owned commercial affiliates in key European markets (Austria, Germany, UK, France, Italy, Poland) and a network of distribution partners across 70+ countries spanning Asia-Pacific, the Middle East, CIS, Russia, Latin America, and North America; and (2) contract development and manufacturing organization (CDMO) services for third-party pharmaceutical companies, leveraging its sterile fill-finish capabilities for biologics up to BSL 2 and high-potency substances up to OEB 5. The company holds broad regulatory certifications including EU GMP, ISO 13485, ISO 14001, ANVISA, CFDA, PDMA, GCC, and RU-GMP, enabling global market access. Ownership remains with the Hillebrand family, and the company continues to invest in geographic expansion, new product authorizations, and ecosystem partnerships (including a minority investment in AI neurorehabilitation startup Nyra Health).
EVER Pharma firmographics
Firmographics- Name
- EVER Pharma
- Legal name
- EVER Neuro Pharma GmbH
- Website
- https://everpharma.com
- Company type
- Private
- Founded year
- 1934
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- EVER Pharma is a privately held, family-owned Austrian specialty pharmaceutical company developing, manufacturing, and selling differentiated injectable generics and CDMO services across neurology, oncology, anesthesia, and critical care in 70+ countries.
- Ownership category
- akta.pro rank
EVER Pharma industry classification
Industry- Product category
- Specialty Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)
Keywords
Where EVER Pharma is headquartered
LocationHeadquarters
- HQ city
- Unterach
- HQ country
- Austria
- HQ region
- Europe
Offices12 records
Markets served
EVER Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Infrastructure, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Specialty Generic Pharmaceuticals: Development, manufacturing and sale of specialty generic injectable pharmaceuticals across neurology, oncology, anesthesia, and critical care therapeutic areas. Products include Cerebrolysin, Dacepton (Apomorphine), Fulvestrant, Dexmedetomidine, Cabazitaxel, Pemetrexed, Azacitidin, Bortezomib, and testosterone products. Revenue from product sales to hospitals, clinics, and healthcare providers globally.
- CDMO Services: Contract development and manufacturing organization services for sterile injectables including vials, ampoules, pre-filled syringes, cartridges, and implants. Services include formulation development, analytical testing, stability studies, and fill-finish manufacturing for third-party pharmaceutical companies.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
EVER Pharma product offering
Product offeringCore offering
EVER Pharma develops, manufactures, and globally distributes specialty generic injectable pharmaceuticals for neurology (Parkinson's disease treatments), oncology, anesthesia, and critical care, alongside a CDMO business offering contract development and aseptic fill-finish manufacturing of sterile injectables for third-party pharmaceutical companies.
Product overview
EVER Pharma is a global pharmaceutical company specializing in neurology, critical care, anaesthesia, and oncology. The company operates as a specialty pharmaceutical manufacturer offering a portfolio of branded generic injectables combined with CDMO (Contract Development and Manufacturing Organization) services. The product portfolio includes neurological therapies such as Cerebrolysin® and the D-mine® therapy package (D-mine® Pump, D-mine® Pen, and Dacepton®/Apomorphine) for Parkinson's disease; oncology products including Fulvestrant, Azacitidin, Cabazitaxel, Pemetrexed, Bortezomib, and Trabectedin; and anesthesia/critical care products including Dexmedetomidine. The company also provides comprehensive CDMO services including contract development and contract manufacturing of sterile injectables. Products are developed in Austria and manufactured in EU GMP-certified facilities in Austria and Germany. Founded in 1934, EVER Pharma distributes products in over 70 countries through international affiliates.
Differentiator
Problem solved
Functional benefit
Brands
- Cerebrolysin: Product brand for neurological therapy products
- Dacepton
- D-mine
Products and services
- Cerebrolysin® Neuropeptide injectable product for neurological disorders, sold to hospitals and healthcare providers as part of EVER Pharma's neurology portfolio.
- Dacepton® (Dopaceptin®, Apomorphine Hydrochloride) Apomorphine hydrochloride injectable for Parkinson's disease administered via continuous subcutaneous infusion as part of the D-mine therapy package.
- D-mine® Pump CE-approved portable micro-infusion pump for precise continuous subcutaneous drug delivery in Parkinson's disease patients, part of the D-mine therapy package.
- Fulvestrant EVER Pharma Injectable antiestrogen for breast cancer treatment, first and only Fulvestrant in Europe approved for room temperature storage, eliminating cold-chain requirements.
- Dexmedetomidine EVER Pharma Injectable anesthetic for procedural and ICU sedation, first and only Dexmedetomidine in Europe for both adult procedural sedation and ICU sedation.
- Azacitidin EVER Pharma Oncology injectable for myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia, available in 100mg and 150mg vial presentations.
- Cabazitaxel EVER Pharma Oncology injectable for metastatic castration-resistant prostate cancer using a single-vial formulation that avoids pre-dilution, reducing preparation time and wastage.
- Pemetrexed EVER Pharma Liquid injectable for malignant pleural mesothelioma and non-small cell lung cancer, formulated as a ready-to-use liquid with room temperature storage.
- Bortezomib EVER Pharma Liquid, ready-to-use injectable for multiple myeloma treatment, eliminating reconstitution steps.
- Trabectedin EVER Pharma Oncology injectable for soft tissue sarcoma, part of EVER Pharma's specialty oncology portfolio.
- Testosterone Enantate / Testosterone Undecanoat EVER Pharma Injectable hormone replacement therapy products for testosterone deficiency, sold in European markets following EU marketing authorization.
- CDMO Services (Contract Development and Manufacturing) Contract Development and Manufacturing Organization services covering sterile fill-finish, aseptic processing, terminal sterilization, biologics up to BSL 2, high-potency substance handling up to OEB 5, and analytical and stability services across vials, ampoules, pre-filled syringes, cartridges, and implants, sold to third-party pharmaceutical companies.
Quantifiable outcome
- Eliminates need for refrigeration storage and transport for Fulvestrant
- +3 more outcomes
Companies that use EVER Pharma
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles2 records
EVER Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
EVER Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Paracelsus Medical Private University (PMU)coreEVER Pharma sponsors the 'EVER Pharma Auditorium' at PMU's House D dedicated to pharmacy. The partnership includes joint research projects in product innovation and improvement, student industrial internships, and company facility visits for pharmacy students.
- Healthcare InstitutionscoreDistribution partnership with hospital purchasing organizations and healthcare institutions across Europe for specialty injectable pharmaceuticals including Azacitidin, Cabazitaxel, and Pemetrexed.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
EVER Pharma competitors and assessment
Company assessmentDirect peers
- Hikma Pharmaceuticals: Hikma is a UK-listed specialty pharmaceutical company with a large injectable generics business focused on oncology, anesthesia, and hospital injectables across the US, Europe, and MENA — directly comparable to EVER Pharma's specialty injectable generics portfolio and multi-region distribution model.
- Stada Arzneimittel: Stada is a European-focused specialty generics and consumer health company with strong positions in CNS, oncology, and injectable specialty products, making it a close peer in geography, therapeutic mix, and product type to EVER Pharma.
- Gland Pharma: Gland Pharma is an India-based pure-play sterile injectable manufacturer supplying regulated markets, now owned by Sanofi. Its focus on small-molecule and complex injectable manufacturing for global generics aligns closely with EVER Pharma's specialty injectable model and CDMO ambitions.
- Polpharma Group: Polpharma is a Central European pharmaceutical manufacturer with portfolio breadth in generics, specialty injectables, and active pharmaceutical ingredients — a comparable mid-sized, regionally rooted European specialty pharma company with hospital-channel focus.
- Vetter Pharma: Vetter is a German-headquartered CDMO specializing in aseptic fill-finish of sterile injectables, including pre-filled syringes and complex biologics — directly comparable to EVER Pharma Jena's CDMO offering in capabilities, customer base, and regulatory profile.
- Apotex: Apotex is a Canadian private/generic pharmaceutical manufacturer with an injectable portfolio and international affiliates — a peer along generics manufacturing scale and multi-region commercial footprint, similar to EVER Pharma's Formative Pharma Canada and broader distribution.
Broad incumbents
- Sandoz (Novartis): Sandoz is the world's largest generic injectable player post-2023 spin-off, with broad portfolio overlap in oncology and hospital injectables — a broad incumbent competing with EVER Pharma across multiple molecules, though at far greater scale and across more geographies.
- Teva Pharmaceutical Industries: Teva is a global generics giant with significant sterile injectable and CNS franchise — a broad incumbent overlapping EVER Pharma's specialty injectable and neurology positioning, but operating at far larger scale with broader therapeutic coverage.
- Catalent: Catalent is a leading global CDMO with major sterile injectable fill-finish capabilities, now part of Novo Holdings — a broad incumbent competing for the same third-party sterile injectable CDMO contracts EVER Pharma Jena is targeting.
Emerging players
- Aenova Group: Aenova is a European CDMO with sterile injectable capabilities targeting pharmaceutical companies, comparable to EVER Pharma Jena's CDMO services but with a narrower specialty injectable focus relative to EVER's broader portfolio offering.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
EVER Pharma social profiles
Digital presenceEVER Pharma compliance and trust
Trust signalCompliance9 records
EVER Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
EVER Pharma leadership team
Management profileNumber of profiles
Profiles7 records
EVER Pharma subsidiaries and ownership
Company hierarchySubsidiaries16 records
EVER Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EVER Pharma M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EVER Pharma
What does EVER Pharma do?
EVER Pharma develops, manufactures, and globally distributes specialty generic injectable pharmaceuticals for neurology (Parkinson's disease treatments), oncology, anesthesia, and critical care, alongside a CDMO business offering contract development and aseptic fill-finish manufacturing of sterile injectables for third-party pharmaceutical companies.
Is EVER Pharma a public or private company?
EVER Pharma is a private company. It is classified as family owned and is currently operating.
When was EVER Pharma founded?
EVER Pharma was founded in 1934. It employs 251 to 500 people.
Where is EVER Pharma based?
EVER Pharma is headquartered in Unterach, Austria, in the Europe region.
How does EVER Pharma make money?
Two revenue lines are on record. Specialty Generic Pharmaceuticals are the primary driver. The others are CDMO Services.
Who are EVER Pharma's main competitors?
Direct peers on record are Hikma Pharmaceuticals, Stada Arzneimittel, Gland Pharma, Polpharma Group, Vetter Pharma and Apotex. Broad incumbents are Sandoz (Novartis), Teva Pharmaceutical Industries and Catalent. Aenova Group is listed as an emerging player.
Does EVER Pharma have an API?
No public API is recorded for EVER Pharma.
What industry is EVER Pharma in?
EVER Pharma's product category is Specialty Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.